Aduhelm, Pazdur, pharma digital & '21 wrap

BioCentury’s podcast team picks the wins for biotech this year

On the latest BioCentury This Week podcast, BioCentury’s editors discuss what the dramatic price cut for Aduhelm aducanumab-avwa means for Biogen Inc. (NASDAQ:BIIB) and the anti-β-amyloid therapies for Alzheimer’s disease nearing regulatory submissions. They also discuss FDA oncology chief Rick Pazdur’s call for PD-1 players to begin collaborating and eliminate redundancy; how digital is evolving at pharmas; and biotech’s bright spots in 2021.